Hansa Biopharma — Juli 2022
-
Penser Access: Snygg finansieringslösning - Hansa Biopharma
-
"Efter rapporten och den annonserade kapitalanskaffningen upprepar vi vårt fundamentala motiverade värde om 240-250 kronor per aktie. Vi bedömer att närmsta 12 månader kommer erbjuda flertalet triggers som kan minska värdegapet till vårt motiverade värde."
-
TA-Video - Opdatering på Bavarian, Genmab, Zealand Pharma, Hansa Biopharma og Novo.
-
..blot som hver eneste gang i biotek.. et vildt rally på lidt positivt, men planen er jo den samme som før og tidshorizonten tillige. Så nogen tager gevinst og så følges der trop. Overvejede såmænd selv at tage 50% ud af samme årsag (for at købe senere), men gjorde det ikke..
-
Hanza Q2’22: Significantly Above Preliminary Figures (Redeye)
"Redeye will likely increase its forecasts and Base Case following a strong Q2 report, with numbers significantly above the preliminary figures. While Main Markets matched our forecasts more or less, Other Markets outperformed our expectations significantly, indicating the investments are paying off."
-
"While Main Markets came in as expected in terms of EBITA, Other Markets EBITA beat our expectations by over 100%. After some quarters with soft margins (Q1 was 1.3%, for example), Q2 strongly indicates that the investments in Other Markets have started to pay off."
-
(-: Glasset er vist halvt fyldt.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind